Paige
New York
About Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., and colleagues from Memorial Sloan Kettering Cancer Center. The Company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of diagnostic devices positioned to drive the future of pathology, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s lightweight platform was purpose-built with pathologists to offer an intuitive user experience, and minimize IT burden and costs while ensuring patient safety and data privacy. Paige’s products deliver insights to pathologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $220.0M
- Funding stage: M&A
- Last round: Series C (Jan 2021)
- Website: paige.ai
- Phone: [email protected]
Industries & Categories
Biopharma, Health Care, Health Diagnostics, Software
Social Profiles
Canonical: https://fsome.com/organization/paige-58228 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.